AI-designed drugs could be commercially available by the end of the decade, according to Alex Zhavoronkov, CEO of Insilico Medicine.

In a Bloomberg Television interview, he expressed confidence that these drugs might emerge within the next five to six years.

The pharmaceutical industry is exploring AI’s potential to lower costs and expedite development timelines.

However, no AI-developed drugs have received regulatory approval to date.

Zhavoronkov noted that Insilico Medicine employs AI at all stages of drug development, from generating hypotheses and optimizing candidates for human trials.

🔗 Source: Bloomberg

🧠 Food for thought

1️⃣ The economics of AI-driven drug development represents a potential industry revolution

The traditional drug development process costs an average of US$2.6 billion and takes approximately 12 years from discovery to market, creating significant barriers to innovation 1.

AI technologies are projected to generate between US$60 billion and US$110 billion annually for the pharmaceutical industry according to McKinsey estimates, while potentially reducing costs by nearly US$100 billion per year 21.

These economic impacts stem from AI’s ability to analyze millions of compounds rapidly, predict clinical outcomes earlier, and optimize research resources toward the most promising candidates 1.

Insilico Medicine’s progress represents this broader industry shift, with over 450 life sciences companies now integrating AI into their drug discovery processes, indicating widespread recognition of the technology’s transformative potential 3.

The financial efficiency gains could fundamentally alter the industry’s risk-reward calculations, potentially enabling more diverse drug development programs and therapies for previously underfunded disease areas.

2️⃣ A competitive race is accelerating AI drug discovery timelines

The prediction of commercially available AI-designed drugs within 5-6 years is supported by the competitive landscape, with at least 18 pharmaceutical companies and more than 75 startups now applying AI in drug discovery 4.

Insilico Medicine isn’t alone in advancing AI-designed molecules to clinical trials – Exscientia has already moved AI-designed drug candidates to clinical testing, while Takeda’s AI-selected psoriasis drug is in final clinical testing with results expected this year 45.